Sagimet Biosciences Inc. (SGMT) – What Are Investment Firms Saying About This Stock?

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $26.07.

A number of equities analysts recently issued reports on the company. Citigroup reaffirmed a “market outperform” rating on shares of Sagimet Biosciences in a report on Friday, November 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Barclays raised shares of Sagimet Biosciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $8.00 to $18.00 in a research report on Wednesday, September 9th. Citizens Jmp cut their price target on shares of Sagimet Biosciences from $29.00 to $27.00 and set a “market outperform” rating on the stock in a research note on Thursday, October 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, October 15th.

Read Our Latest Research Report on SGMT

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in Sagimet Biosciences during the third quarter worth approximately $17,784,000. Entropy Technologies LP purchased a new stake in Sagimet Biosciences in the third quarter valued at approximately $182,000. AWM Investment Company Inc. lifted its stake in Sagimet Biosciences by 275.0% in the third quarter. AWM Investment Company Inc. now owns 300,000 shares of the company’s stock valued at $2,964,000 after buying an additional 220,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Sagimet Biosciences in the third quarter valued at approximately $7,433,000. Finally, Empowered Funds LLC purchased a new position in Sagimet Biosciences during the 3rd quarter worth $328,000. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Sagimet Biosciences Trading Up 2.6%

Shares of SGMT opened at $10.11 on Friday. Sagimet Biosciences has a twelve month low of $4.50 and a twelve month high of $11.45. The firm’s fifty day simple moving average is $9.83 and its 200-day simple moving average is $7.75. The firm has a market capitalization of $628.44 million, a price-to-earnings ratio of -8.50 and a beta of 3.43.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.05). On average, analysts predict that Sagimet Biosciences will post -1.26 earnings per share for the current fiscal year.

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Featured Stories

Analyst Recommendations for Sagimet Biosciences (NASDAQ:SGMT)

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.